

Supplementary Table 1. Cox regression analysis for risk factors associated with PTDM diagnosed after 1 year

Factor	Univariable analysis		Multivariable analysis ^a	
	HR (95% CI)	P value	HR (95% CI)	P value
Age, yr	1.00 (0.97–1.03)	0.980	1.00 (0.97–1.04)	0.889
Sex (ref. male)	0.91 (0.54–1.64)	0.750	1.11 (0.52–2.37)	0.795
BMI, kg/m ²	1.00 (0.92–1.09)	0.944	0.98 (0.89–1.08)	0.679
Fasting glucose	1.01 (0.99–1.04)	0.198	1.02 (0.99–1.05)	0.058
eGFR, mL/min/1.73 m ²	0.99 (0.98–1.00)	0.142	0.99 (0.99–1.01)	0.886
MELD score	1.02 (0.98–1.07)	0.262	1.01 (0.95–1.08)	0.668
Hypomagnesemia	6.26 (1.92–20.37)	0.002	3.13 (0.38–5.32)	0.092
HCV infection (ref. No)	1.00 (0.31–3.21)	0.982	0.54 (0.12–2.37)	0.415
CMV disease (ref. No)	0.80 (0.39–1.62)	0.531	0.58 (0.25–1.32)	0.192
Immunosuppressive agent				
Steroid+CNI (ref)	1.00	>0.999	1.00	>0.999
Steroid+MMF	0.69 (0.31–1.54)	0.369	0.63 (0.27–1.46)	0.285
Steroid+mTORi	0.79 (0.11–5.75)	0.816	1.09 (0.16–8.42)	0.930
Follow-up duration, yr	1.07 (0.98–1.12)	0.091	1.03 (0.65–1.27)	0.254
Baseline muscle index	1.00 (0.99–1.01)	0.471	0.99 (0.98–1.01)	0.277
ΔMuscle area, cm ² /m ²	1.02 (1.01–1.04)	<0.001	1.03 (1.01–1.05)	<0.001

PTDM, post-transplant diabetes mellitus; HR, hazard ratio; CI, confidence interval; BMI, body mass index; eGFR, estimated glomerular filtration rate; MELD, model for end-stage liver disease; HCV, hepatitis C virus; CMV, cytomegalovirus; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; mTORi, mammalian target of rapamycin inhibitor.

^aModel adjusted for age, sex, BMI, eGFR, hypomagnesemia, HCV infection, CMV disease, and immunosuppressive agents.